Janux Therapeutics (NASDAQ:JANX) Hits New 1-Year Low After Analyst Downgrade

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) reached a new 52-week low on Tuesday after Clear Str downgraded the stock from a strong-buy rating to a hold rating. The company traded as low as $12.80 and last traded at $13.0330, with a volume of 343731 shares. The stock had previously closed at $13.76.

JANX has been the subject of several other research reports. Barclays decreased their target price on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Cantor Fitzgerald reduced their price objective on Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a report on Wednesday, October 8th. Piper Sandler lowered their target price on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a research report on Friday, January 16th. Finally, Wolfe Research began coverage on Janux Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Eleven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $60.08.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 8,072 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the sale, the chief executive officer directly owned 284,982 shares in the company, valued at $3,912,802.86. This represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Zachariah Mciver sold 2,714 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $37,263.22. Following the completion of the sale, the insider directly owned 23,286 shares in the company, valued at $319,716.78. This represents a 10.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 42,364 shares of company stock valued at $972,185 over the last three months. 8.10% of the stock is owned by company insiders.

Key Headlines Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Major collaboration with Bristol Myers Squibb to develop a tumor‑activated oncology therapy; deal reported to include up to ~$800–850M in potential payments, giving Janux validation, non‑dilutive funding potential and a large partner to advance development. Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
• Positive Sentiment: Recent quarterly results beat expectations (EPS and revenue), showing execution ahead of this deal and reducing near‑term cash worries; that fundamental beat supports the positive market reaction. Janux Therapeutics Trading and Earnings Summary
• Neutral Sentiment: Widespread media coverage amplified pre‑market buying; different outlets reported slightly different deal numbers (Benzinga cited $800M while Reuters cited up to $850M), so investors should await the company’s filing for precise economics and timing. Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
• Negative Sentiment: Analyst pressure: Clear Street recently downgraded JANX from “strong‑buy” to “hold,” which could cap upside if investors seek fresh analyst support; monitor any follow‑up analyst notes for changed models or price targets. Clear Street downgrades Janux Therapeutics (JANX)

Hedge Funds Weigh In On Janux Therapeutics

Institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System increased its position in Janux Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock worth $858,000 after purchasing an additional 404 shares during the last quarter. ProShare Advisors LLC lifted its position in Janux Therapeutics by 8.1% during the 2nd quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock worth $238,000 after acquiring an additional 771 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Janux Therapeutics by 25.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after purchasing an additional 820 shares during the last quarter. Virtus Investment Advisers LLC boosted its position in shares of Janux Therapeutics by 37.9% in the second quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock valued at $85,000 after acquiring an additional 1,011 shares during the period. Finally, DNB Asset Management AS boosted its holdings in Janux Therapeutics by 19.2% in the 2nd quarter. DNB Asset Management AS now owns 9,253 shares of the company’s stock valued at $214,000 after purchasing an additional 1,488 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

The stock has a market capitalization of $910.67 million, a P/E ratio of -9.01 and a beta of 2.88. The firm has a 50 day moving average of $18.55 and a 200-day moving average of $22.82.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.21. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $3.07 million. As a group, equities analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.